<DOC>
	<DOCNO>NCT01717326</DOCNO>
	<brief_summary>This study safety efficacy grazoprevir ( MK-5172 ) combination elbasvir ( MK-8742 ) ± ribavirin ( RBV ) . The primary efficacy endpoint Sustained Virologic Response 12 week end study therapy ( SVR12 ) treatment arm .</brief_summary>
	<brief_title>A Study Combination Regimen Grazoprevir ( MK-5172 ) Elbasvir ( MK-8742 ) ± Ribavirin Participants With Chronic Hepatitis C ( MK-5172-035 )</brief_title>
	<detailed_description>Part A do treatment-naïve ( TN ) , genotype 1 ( GT1 ) , interferon eligible , non-cirrhotic ( N-C ) participants chronic hepatitis C ( CHC ) . Participants assign randomly 1 2 treatment arm receive grazoprevir 100 mg daily ( QD ) + elbasvir 20 mg 50 mg QD twice daily ( BID ) RBV , treatment arm receive grazoprevir 100 mg QD + elbasvir 50 mg QD without RBV . Treatment last 12 week . In Part B , participant hepatitis C virus ( HCV ) GT1 HCV ribonucleic acid ( RNA ) level ≥10,000 IU/mL randomly assign study arm , base absence presence cirrhosis ( C ) , whether TN poor response previous antiviral therapy ( null responder [ NR ] ) , whether co-infected human immunodeficiency virus ( HIV ) ; participant receive open-label grazoprevir ( 100 mg ) combination elbasvir ( 50 mg ) ± RBV . Treatment last 8 18 week dependent arm assignment . In Part C , TN , N-C participant HCV GT1b HCV RNA level ≥10,000 IU/mL randomly assign receive open-label grazoprevir ( 100 mg ) combination elbasvir ( 50 mg ) ± RBV . Treatment last 8 week . In Part D , TN N-C participant HCV GT3 HCV RNA level ≥10,000 IU/mL randomly assign receive open-label grazoprevir ( 100 mg ) combination elbasvir ( 50 mg ) + RBV 12 18 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Inclusion criterion : All participant CHC genotype 1 ( GT1 ) virus infection ( Parts A , B , C ) GT3 virus infection ( Part D ) Female participant childbearing potential male participant female partner childbearing potential , must use two acceptable method birth control ≥2 week prior Day 1 ≥6 month last dose study drug , longer dictate local regulation Part A Absence ( medical history physical finding ) ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom advance liver disease , cirrhosis No evidence advance fibrosis , cirrhosis and/or hepatocellular carcinoma biopsy noninvasive testing ( FibroScan and/or FibroTest ) Parts B , C , D Treatment naïve without cirrhosis , Prior treatment failure PegIFN/Ribavirin without cirrhosis , Coinfected human immunodeficiency virus ( HIV ) without cirrhosis Absence ( medical history physical finding ) ascites , bleed esophageal varix , hepatic encephalopathy , sign symptom advance liver disease Liver disease stag assessment liver biopsy noninvasive testing ( FibroScan and/or FibroTest ) Exclusion criterion : All participant NonGT1 HCV infection ( Part A , Part B , Part C ) nonGT3 HCV infection ( Part D ) include mixed GT infection ( nonGT1 [ Part A , Part B , Part C ] nonGT3 [ Part D ] ) nontypeable genotype Evidence hepatocellular carcinoma ( HCC ) evaluation HCC Currently participate participate study investigational compound within 30 day sign informed consent willing refrain participate another study Diabetic and/or hypertensive clinically significant ocular examination finding History depression associate hospitalization depression , electroconvulsive therapy , result prolonged absence work and/or significant disruption daily function Suicidal homicidal ideation and/or attempt , history severe psychiatric disorder Clinical diagnosis substance abuse Current history seizure disorder , stroke , transient ischemic attack Immunologically mediate disease Chronic pulmonary disease Clinically significant cardiac abnormalities/dysfunction Active clinical gout within last year Hemoglobinopathy myelodysplastic syndrome History organ transplant include hematopoietic stem cell transplant Poor venous access Indwelling venous catheter History gastric surgery malabsorption disorder Severe concurrent disease Evidence active suspect malignancy , history malignancy , ≤5 year Pregnant , lactating , expect conceive donate egg Male participant pregnant female partner Member/family member investigational study sponsor staff directly involve study Evidence history chronic hepatitis cause HCV Part A Not treatmentnaïve Documented HIV positive Taking planning take significant inducer inhibitor CYP3A4 substrates herbal supplement 2 week prior start study medication Parts B , C , D Previously receive HCV directacting antiviral Requiring , likely require , chronic systemic administration corticosteroid course trial For participant diagnose diabetes mellitus , document HbA1c &gt; 8.5 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>